`
`RESEARCH
`
`APPLICA TION NUMBER:
`
`NDA 22-253 & 22-254
`
`MICROBIOLOGY REVIEW! S!
`
`
`
`Product Quality Microbiology Review
`
`1 June 2008
`
`NDA:
`
`22—254
`
`Drug Product Name
`Lacosamide
`Proprietary:
`(R) -2-acetomido-N-benzyl—3-
`Non-proprietary:
`methoxypropionamide
`Drug Product Priority Classification: 81
`
`Review Number:
`
`1
`
`Dates of Submission(s) Covered by this Review
`Letter
`Stamp
`Review Request
`
`.
`Assrgned to
`Rev1ewer
`
`September 28,
`2007
`
`October 1, 2007
`
`November 20,
`2007
`
`November 21,
`2007
`
`Submission History (for amendments only) — N/A
`
`Applicant/Sponsor
`Name:
`
`Address:
`
`Schwarz Biosciences
`
`P.O.B0X 1101.67, Research Triangle Park, NC
`27709
`
`Representative:
`Telephone:
`
`Alan L. Blumberg, Sr. Dir. Global Reg. Affairs
`919—767—25 13 (phone), 919-767-3139 (fax)
`
`Name of Reviewer:
`
`Vinayak B. Pawar, Ph.D.
`
`Conclusion:
`
`The application is recommended for approval from
`microbiology product quality standpoint.
`
`
`
`NDA 22-254
`
`Microbiology Review # 1
`
`Product Quality Microbiology Data Sheet
`
`A.
`
`1.
`
`2.
`
`TYPE OF SUBMISSION:
`
`Original NDA
`
`SUBMISSION PROVIDES FOR: An injectable form of a drug
`previously approved in a tablet form.
`
`{.
`
`MANUFACTURING SITE: -
`
`
`I. _’—"”'\
`
`DOSAGE FORM, ROUTE OF ADMINISTRATION AND
`
`STRENGTH/POTENCY:
`
`10mg/mL
`
`METHOD(S) OF STERILIZATION:
`
`
`
`PHARMACOLOGICAL CATEGORY: For treatment of partial-onset
`seizures.
`
`B.
`
`C.
`
`SUPPORTING/RELATED DOCUMENTS: NDA 22—253 2 5
`
`REMARKS: The consult requests review of an original NDA 22-254 for an
`injectable form of Lacosamide (SPM927) Injection. This application is a GRMP
`pilot application. The submission is in electronic form in EDR. Initial Quality
`Assessment has been filed by Martha Heinman on October 30, 2007.
`
`filename: C:\my documents\review\NDA\N022254R1
`
`M4}
`
`M4)
`
`23(4)
`
`APPEARS THIS WAY
`0N ORIGINAL
`
`Page 2 of 17
`
`
`
`NDA 22-254
`Microbiology Review # 1
`
`
`Executive Summary
`
`1.
`
`Recommendations
`
`A.
`
`B.
`
`Recommendation on Approvability — The application is
`recommended for approval from microbiology product quality
`standpoint.
`Recommendations on Phase 4 Commitments and/or
`
`Agreements, if Approvable - NA
`
`11.
`
`Summary of MicrobiologyAssessments
`
`A.
`
`B.
`
`C.
`
`Brief Description of the Manufacturing Processes that relate to
`Product Quality Microbiology — N
`/
`.
`/
`I
`/
`v /
`//
`(
`
`_
`
`,
`
`51(4)
`
`Brief Description of Microbiology Deficiencies — None.
`
`Assessment of Risk Due to Microbiology Deficiencies — None.
`
`III.
`
`Administrative
`
`A.
`
`B.
`
`C.
`
`Reviewer's Signature
`
`Vinayak B. Pawar, Ph.D.
`
`Endorsement Block
`
`CC Block
`N/A
`
`James McVey
`
`——-————————-—_———_—_—
`
`Page 3 of 17
`
`
`
`-_
`
`M‘- Page(s) Withheld
`
`/Trade Secret/Confidential (b4)
`
`Draft Labeling (b4) i
`
`‘ Draft Labeling (b5)
`
`Deliberative Process (b5)
`
`
`
`This is a representation of an electronic record that was signed electronically and
`this page is the manifestation of the electronic signature.
`
`Vinayak Pawar
`6/4/2008 03:09:05 PM
`MICROBIOLOGIST
`
`The application is recommended for approval from microbiology product
`quality standpoint.
`
`James McVey
`6/4/2008 03:13:31 PM
`MICROBIOLOGIST
`I concur
`
`